MET exon 14 Skipping Mutations: Essential Considerations for Current Management of Non –Small-Cell Lung Cancer

Genetic alterations in MET that lead to exclusion of exon 14 from the transcript are now ‘targetable’ in non-small cell lung cancer (NSCLC) following recent drug approvals for this indication. However, this class of alteration is much more diverse than activating mutations in other targetable oncogenes, which presents challenges for clinical detection by molecular diagnostic assays. For this reason, MET exon 14 (METex14) skipping was highlighted in the Association for Molecular Pathology Emerging and Evolving Biomarkers webinar series (https://www.amp.org/education/emerging-and-evolving-biomarkers/, date of last access: April 26, 2022)
Source: Journal of Molecular Diagnostics - Category: Pathology Authors: Tags: Practice Advances Source Type: research